TXMD

TherapeuticsMD, Inc. (TXMD) SWOT Analysis Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 3.4 (Weak)

Negative cash conversion cycle indicates working-capital efficiency versus peers, but TXMD’s negative ROIC shows capital deployment still destroys value relative to profitable competitors.

Current and quick ratios above 3.0 suggest near-term liquidity is stronger than many distressed peers, yet this does not translate into durable operating advantage.

Low debt-to-equity supports balance-sheet flexibility versus more levered peers, although the benefit is limited because leverage remains secondary to weak earnings power.

Weaknesses

Score:

Negative TTM ROIC is the clearest structural weakness, because TXMD is still earning below its cost of capital while stronger peers compound value.

A net debt-to-EBITDA ratio near 0.9 is manageable, but it still constrains strategic optionality more than cash-rich peers with cleaner capital structures.

The absence of disclosed positive margin metrics signals limited pricing power and scale efficiency versus peers, which keeps profitability structurally fragile.

Opportunities

Score:

Further monetizing the negative cash conversion cycle could release working capital faster than peers, improving liquidity without requiring immediate revenue growth.

If TXMD converts its strong current ratio into sustained operating discipline, it could narrow the gap with peers that rely on external financing.

Lower leverage than many peers creates room for operational restructuring or selective investment, which could improve competitive positioning over a 2–5 year horizon.

Threats

Score:

Persistent negative ROIC leaves TXMD vulnerable to better-capitalized peers that can outinvest it in commercialization, product development, and customer acquisition.

Because margin data are not positive or disclosed, peers with proven scale economics can sustain lower prices and pressure TXMD’s positioning.

Moderate leverage is not excessive, but in a weak earnings environment it can still amplify downside versus peers with stronger cash generation.

Overall Score

Score:

TXMD’s structural positioning versus peers is weak because liquidity and working-capital efficiency are outweighed by persistent value destruction and limited profitability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on TherapeuticsMD, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →